An overview of polyamine metabolism in pancreatic ductal adenocarcinoma

被引:25
|
作者
Phanstiel, Otto [1 ]
机构
[1] Univ Cent Florida, Coll Med, Dept Med Educ, Orlando, FL 32826 USA
关键词
polyamines; pancreatic ductal adenocarcinoma; polyamine transport; metabolism; ORNITHINE-DECARBOXYLASE; HEPARAN-SULFATE; CANCER-CELLS; TRANSPORT INHIBITORS; EPITHELIAL-CELLS; NITRIC-OXIDE; REGULATES GROWTH; MAMMALIAN-CELLS; CARCINOMA CELLS; TISSUE-CULTURE;
D O I
10.1002/ijc.31155
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest major cancers, with a five year survival rate of less than 8%. With current therapies only giving rise to modest life extension, new approaches are desperately needed. Even though targeting polyamine metabolism is a proven anticancer strategy, there are no reports, which thoroughly survey the literature describing the role of polyamine biosynthesis and transport in PDAC. This review seeks to fill this void by describing what is currently known about polyamine metabolism in PDAC and identifies new targets and opportunities to treat this disease. Due to the pleiotropic effects that polyamines play in cells, this review covers diverse areas ranging from polyamine metabolism (biosynthesis, catabolism and transport), as well as the potential role of polyamines in desmoplasia, autophagy and immune privilege. Understanding these diverse roles provides the opportunity to design new therapies to treat this deadly cancer via polyamine depletion.
引用
收藏
页码:1968 / 1976
页数:9
相关论文
共 50 条
  • [21] Pancreatic Ductal Adenocarcinoma
    Heinemann, V.
    Schmidberger, H.
    ONKOLOGE, 2019, 25 (08): : 642 - 644
  • [22] Pancreatic ductal adenocarcinoma
    Gallmeier, E.
    Gress, T. M.
    GASTROENTEROLOGE, 2019, 14 (02): : 131 - 148
  • [23] Pancreatic Ductal Adenocarcinoma
    Erickson, Lori A.
    MAYO CLINIC PROCEEDINGS, 2017, 92 (09) : 1461 - 1462
  • [24] Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview
    Panchal, Kanan
    Sahoo, Rakesh Kumar
    Gupta, Umesh
    Chaurasiya, Akash
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 95
  • [25] SYNERGISTIC ANTITUMOR EFFICACY OF GEMCITABINE AND CISPLATIN TO INDUCE FERROPTOSIS IN PANCREATIC DUCTAL ADENOCARCINOMA VIA SAT1-POLYAMINE METABOLISM PATHWAY
    Wei, Wanhui
    Lu, Yuanyuan
    Hu, Qian
    Zhang, Heng
    Zhao, Qiu
    Liu, Lan
    GASTROENTEROLOGY, 2023, 164 (06) : S772 - S773
  • [26] Oxygen metabolism and hypoxia tolerance in organoid models of pancreatic ductal adenocarcinoma
    Zhang, Ji
    Liu, Qingquan
    Cojocari, Dan
    Zaidi, Mark
    McKee, Trevor
    Radulovich, Nikolina
    Tsao, Ming-Sound
    Hedley, David
    Koritzinsky, Marianne
    Wouters, Bradly G.
    CANCER RESEARCH, 2018, 78 (13)
  • [27] Metabolic Imaging of Pancreatic Ductal Adenocarcinoma Detects Altered Choline Metabolism
    Penet, Marie-France
    Shah, Tariq
    Bharti, Santosh
    Krishnamachary, Balaji
    Artemov, Dmitri
    Mironchik, Yelena
    Wildes, Flonne
    Maitra, Anirban
    Bhujwalla, Zaver M.
    CLINICAL CANCER RESEARCH, 2015, 21 (02) : 386 - 395
  • [28] Markers of Bone Metabolism in Patients With Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma
    Pezzilli, Raffaele
    d'Eril, Gian Vico Melzi
    Barassi, Alessandra
    MEDICINE, 2015, 94 (42) : e1754
  • [29] Pancreatic Ductal Adenocarcinoma Derived From IPMN and Pancreatic Ductal Adenocarcinoma Concomitant With IPMN
    Yamaguchi, Koji
    Kanemitsu, Shuichi
    Hatori, Takashi
    Maguchi, Hiroyuki
    Shimizu, Yasuhiro
    Tada, Minoru
    Nakagohri, Toshio
    Hanada, Keiji
    Osanai, Manabu
    Noda, Yutaka
    Nakaizumi, Akihiko
    Furukawa, Toru
    Ban, Shinichi
    Nobukawa, Bunsei
    Kato, Yo
    Tanaka, Masao
    PANCREAS, 2011, 40 (04) : 571 - 580
  • [30] Pancreatic ductal adenocarcinoma chemoresistance: From metabolism reprogramming to novel treatment
    Zhang Jingcheng
    Wang Yutong
    Wang Lejunzi
    You Lei
    Zhang Taiping
    中华医学杂志英文版, 2024, 137 (04)